Christiansen P E, Behnke K, Black C H, Ohrström J K, Bork-Rasmussen H, Nilsson J
Novo Nordisk A/S, Bagsvaerd, Denmark.
Acta Psychiatr Scand. 1996 Mar;93(3):158-63. doi: 10.1111/j.1600-0447.1996.tb10623.x.
A total of 144 outpatients in general practice in Denmark, aged 18-65 years and diagnosed as suffering from depression with a HAMD-17 score of 15 or more, were included in this 8-week double-blind, randomised, multicentre, controlled, parallel group comparison of paroxetine versus amitriptyline. The purpose of the study was primarily to evaluate efficacy and tolerance of treatment. In addition, focus was added on weight change and subjective well-being. The efficacy results showed equal effect of both drugs. However, paroxetine was tolerated better than amitriptyline, and this difference reached the level of significance when four non-evaluable patients were taken out of the analysis. Moreover, there was a significant weight increase in the amitriptyline group and no significant weight change in the paroxetine group. There was no difference between the groups as regards subjective well-being as measured by the VAS. In conclusion, paroxetine is an effective and well-tolerated antidepressant, and well-suited for the treatment of depression in general practice.
共有144名丹麦普通门诊患者参与了这项为期8周的双盲、随机、多中心、对照、平行组的帕罗西汀与阿米替林对比研究。这些患者年龄在18至65岁之间，被诊断患有抑郁症，汉密尔顿抑郁量表（HAMD-17）得分在15分及以上。该研究的主要目的是评估治疗的疗效和耐受性。此外，还关注体重变化和主观幸福感。疗效结果显示两种药物效果相当。然而，帕罗西汀的耐受性优于阿米替林，当剔除4名无法评估的患者后进行分析，这种差异达到了显著水平。此外，阿米替林组体重显著增加，而帕罗西汀组体重无显著变化。在通过视觉模拟量表（VAS）测量的主观幸福感方面，两组之间没有差异。总之，帕罗西汀是一种有效且耐受性良好的抗抑郁药，非常适合在普通门诊治疗抑郁症。
